Obecabtagene autoleucel

Therapeutic indications

Obecabtagene autoleucel is indicated for:

B cell precursor acute lymphoblastic leukaemia (B ALL)

Population group: only adults (18 years old or older)

Obecabtagene autoleucel is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B cell precursor acute lymphoblastic leukaemia (B ALL).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Obecabtagene autoleucel is contraindicated in the following cases:

Clinically significant active systemic infections

Infectious disease

Blood, organ, tissue and cell donation

at least one of
Blood unit collection
Organ retrieval operation
Transplantation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2025: AUCATZYL Dispersion for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈